- Home
- SUUN vs ELTX Comparison
SUUN vs ELTX Comparison
Compare SUUN & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- ELTX
- Stock Information
- Founded
- SUUN 2013
- ELTX 2011
- Country
- SUUN Canada
- ELTX United States
- Employees
- SUUN N/A
- ELTX N/A
- Industry
- SUUN
- ELTX Biotechnology: Pharmaceutical Preparations
- Sector
- SUUN
- ELTX Health Care
- Exchange
- SUUN Nasdaq
- ELTX Nasdaq
- Market Cap
- SUUN 75.1M
- ELTX 121.7M
- IPO Year
- SUUN N/A
- ELTX N/A
- Fundamental
- Price
- SUUN $1.99
- ELTX $5.40
- Analyst Decision
- SUUN Strong Buy
- ELTX Strong Buy
- Analyst Count
- SUUN 1
- ELTX 2
- Target Price
- SUUN $6.00
- ELTX $9.50
- AVG Volume (30 Days)
- SUUN 134.5K
- ELTX 34.1K
- Earning Date
- SUUN 05-19-2025
- ELTX 05-19-2025
- Dividend Yield
- SUUN N/A
- ELTX N/A
- EPS Growth
- SUUN N/A
- ELTX N/A
- EPS
- SUUN N/A
- ELTX N/A
- Revenue
- SUUN $36,247,013.00
- ELTX N/A
- Revenue This Year
- SUUN $15.42
- ELTX N/A
- Revenue Next Year
- SUUN $62.53
- ELTX N/A
- P/E Ratio
- SUUN N/A
- ELTX N/A
- Revenue Growth
- SUUN 43.76
- ELTX N/A
- 52 Week Low
- SUUN $1.95
- ELTX $3.34
- 52 Week High
- SUUN $6.87
- ELTX $11.45
- Technical
- Relative Strength Index (RSI)
- SUUN 34.40
- ELTX 51.02
- Support Level
- SUUN $1.96
- ELTX $4.85
- Resistance Level
- SUUN $2.36
- ELTX $5.75
- Average True Range (ATR)
- SUUN 0.15
- ELTX 0.41
- MACD
- SUUN 0.03
- ELTX 0.14
- Stochastic Oscillator
- SUUN 22.50
- ELTX 80.65
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.